MORRISTOWN, N.J., June 28, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), announced today that it has been added to the Russell Microcap® index following the annual reconstitution, which took effect after the US market closed on Friday, June 23rd.
“We are pleased to be included in the Russell Microcap Index,” said John Sedor, Chairman and Chief Executive Officer of Pernix Therapeutics. “The Russell US Indexes are some of the leading US equity benchmarks for institutional investors. We believe inclusion in the Russell Microcap Index should increase our visibility in the financial marketplace and broaden our shareholder base since Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.”
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Treximet® and Silenor® are registered trademarks of Pernix Therapeutics Holdings, Inc.
Zohydro® ER is a registered trademark of Pernix Therapeutics Holdings, Inc.
BeadTek™ is a trademark used by Pernix under license.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anta Sports Expands Global Footprint With Strategic Puma Stake
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



